ArticlePakistan journal of medical sciences2026
Therapeutic efficacy of leuprorelin acetate combined with rhGH in girls with ICPP and Its impact on body height and secondary sexual characteristics.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the therapeutic efficacy of leuprorelin acetate combined with recombinant human growth hormone(rhGH) in girls with idiopathic central precocious puberty(ICPP) and its impacts on body height and secondary sexual characteristics. Methodology: This was a retrospective study. One hundred and fifty-four girls with ICPP admitted to Affiliated Hospital of Putian University between November 2022 to November 2025 were randomly allocated into two groups: the control group (leuprorelin acetate monotherapy) and the study group (leuprorelin acetate plus rhGH), with 77 cases in each group. Therapeutic efficacy, growth parameters, secondary sexual characteristics, serum sex hormone levels, and adverse reactions were compared between the two groups. Results: The overall response rate in the study group was markedly higher than that in the control group( Conclusion: Combination therapy with leuprorelin acetate and rhGH yields substantial therapeutic benefits in girls with ICPP. It may effectively regulate sex hormone levels, facilitates improvements in growth and secondary sexual characteristics, and demonstrate favorable clinical safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.